Estimates of the chromium(VI) reducing capacity in human body compartments as a mechanism for attenuating its potential toxicity and carcinogenicity - PubMed (original) (raw)
Comparative Study
Estimates of the chromium(VI) reducing capacity in human body compartments as a mechanism for attenuating its potential toxicity and carcinogenicity
S De Flora et al. Carcinogenesis. 1997 Mar.
Abstract
Estimates of the overall reducing capacity of hexavalent chromium(VI) in some human body compartments were made by relating the specific reducing activity of body fluids, cell populations or organs to their average volume, number, or weight. Although these data do not have absolute precision or universal applicability, they provide a rationale for predicting and interpreting the health effects of chromium(VI). The available evidence strongly indicates that chromium(VI) reduction in body fluids and long-lived non-target cells is expected to greatly attenuate its potential toxicity and genotoxicity, to imprint a threshold character to the carcinogenesis process, and to restrict the possible targets of its activity. For example, the chromium(VI) sequestering capacity of whole blood (187-234 mg per individual) and the reducing capacity of red blood cells (at least 93-128 mg) explain why this metal is not a systemic toxicant, except at very high doses, and also explain its lack of carcinogenicity at a distance from the portal of entry into the organism. Reduction by fluids in the digestive tract, e.g. by saliva (0.7-2.1 mg/day) and gastric juice (at least 84-88 mg/day), and sequestration by intestinal bacteria (11-24 mg eliminated daily with feces) account for the poor intestinal absorption of chromium(VI). The chromium(VI) escaping reduction in the digestive tract will be detoxified in the blood of the portal vein system and then in the liver, having an overall reducing capacity of 3300 mg. These processes give reasons for the poor oral toxicity of chromium(VI) and its lack of carcinogenicity when introduced by the oral route or swallowed following reflux from the respiratory tract. In terminal airways chromium(VI) is reduced in the epithelial lining fluid (0.9-1.8 mg) and in pulmonary alveolar macrophages (136 mg). The peripheral lung parenchyma has an overall reducing capacity of 260 mg chromium(VI), with a slightly higher specific activity as compared to the bronchial tree. Therefore, even in the respiratory tract, which is the only consistent target of chromium(VI) carcinogenicity in humans (lung and sinonasal cavities), there are barriers hampering its carcinogenicity. These hurdles could be only overwhelmed under conditions of massive exposure by inhalation, as it occurred in certain work environments prior to the implementation of suitable industrial hygiene measures.
Similar articles
- Threshold mechanisms and site specificity in chromium(VI) carcinogenesis.
De Flora S. De Flora S. Carcinogenesis. 2000 Apr;21(4):533-41. doi: 10.1093/carcin/21.4.533. Carcinogenesis. 2000. PMID: 10753182 Review. - Metabolic reduction of chromium, as related to its carcinogenic properties.
De Flora S, Serra D, Camoirano A, Zanacchi P. De Flora S, et al. Biol Trace Elem Res. 1989 Jul-Sep;21:179-87. doi: 10.1007/BF02917250. Biol Trace Elem Res. 1989. PMID: 2484584 Review. - Metabolic reduction of chromium as a threshold mechanism limiting its in vivo activity.
Petrilli FL, de Flora S. Petrilli FL, et al. Sci Total Environ. 1988 Jun 1;71(3):357-64. doi: 10.1016/0048-9697(88)90208-2. Sci Total Environ. 1988. PMID: 3043658 Review. - Ingestion of chromium(VI) in drinking water by human volunteers: absorption, distribution, and excretion of single and repeated doses.
Kerger BD, Finley BL, Corbett GE, Dodge DG, Paustenbach DJ. Kerger BD, et al. J Toxicol Environ Health. 1997 Jan;50(1):67-95. doi: 10.1080/009841097160618. J Toxicol Environ Health. 1997. PMID: 9015133 Clinical Trial.
Cited by
- Effects of Cr(VI) exposure on electrocardiogram, myocardial enzyme parameters, inflammatory factors, oxidative kinase, and ATPase of the heart in Chinese rural dogs.
Lu J, Liu K, Qi M, Geng H, Hao J, Wang R, Zhao X, Liu Y, Liu J. Lu J, et al. Environ Sci Pollut Res Int. 2019 Oct;26(29):30444-30451. doi: 10.1007/s11356-019-06253-0. Epub 2019 Aug 22. Environ Sci Pollut Res Int. 2019. PMID: 31440970 - Chronic occupational exposure to hexavalent chromium causes DNA damage in electroplating workers.
Zhang XH, Zhang X, Wang XC, Jin LF, Yang ZP, Jiang CX, Chen Q, Ren XB, Cao JZ, Wang Q, Zhu YM. Zhang XH, et al. BMC Public Health. 2011 Apr 12;11:224. doi: 10.1186/1471-2458-11-224. BMC Public Health. 2011. PMID: 21481275 Free PMC article. - Hexavalent chromium is carcinogenic to F344/N rats and B6C3F1 mice after chronic oral exposure.
Stout MD, Herbert RA, Kissling GE, Collins BJ, Travlos GS, Witt KL, Melnick RL, Abdo KM, Malarkey DE, Hooth MJ. Stout MD, et al. Environ Health Perspect. 2009 May;117(5):716-22. doi: 10.1289/ehp.0800208. Epub 2008 Dec 31. Environ Health Perspect. 2009. PMID: 19479012 Free PMC article. - Different roles of ROS and Nrf2 in Cr(VI)-induced inflammatory responses in normal and Cr(VI)-transformed cells.
Roy RV, Pratheeshkumar P, Son YO, Wang L, Hitron JA, Divya SP, Zhang Z, Shi X. Roy RV, et al. Toxicol Appl Pharmacol. 2016 Sep 15;307:81-90. doi: 10.1016/j.taap.2016.07.016. Epub 2016 Jul 26. Toxicol Appl Pharmacol. 2016. PMID: 27470422 Free PMC article. - Chemical mechanisms of DNA damage by carcinogenic chromium(VI).
Krawic C, Zhitkovich A. Krawic C, et al. Adv Pharmacol. 2023;96:25-46. doi: 10.1016/bs.apha.2022.07.003. Epub 2022 Aug 26. Adv Pharmacol. 2023. PMID: 36858775 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources